Healthcare & Pharmaceuticals

EU regulator begins real-time review of GSK-Vir COVID-19 antibody drug

3 minute read

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs/File Photo

Register now for FREE unlimited access to

May 7 (Reuters) - Europe's medicines regulator said on Friday it has begun a real-time review of the COVID-19 antibody treatment developed by GSK (GSK.L) and Vir Biotechnology (VIR.O), formally kicking off the process for a potential European Union (EU) approval.

The so-called rolling review comes after the European Medicines Agency (EMA) last month began another review of early data to provide recommendations for national authorities in the trading bloc who may decide on early use of the medicine. read more

The EMA said it kicked off the real-time review based on early results from an ongoing study into how well the treatment, termed sotrovimab or VIR-7831, can prevent hospitalisation or death in non-hospitalised COVID-19 patients.

Register now for FREE unlimited access to

"EMA has not yet received the full dataset and it is too early to draw any conclusions regarding the benefit-risk balance of the medicine," the regulator said, adding that it has started assessing the first batch of data.

GSK and Vir reported in March that their medicine reduced the risk of hospitalisation and deaths among patients by 85%, based on interim clinical data.

Sotrovimab belongs to a class of medicines called monoclonal antibodies, which are synthetically manufactured copies of the human body's natural infection-fighting proteins.

It joins similar drugs from Eli Lilly (LLY.N), Celltrion (068270.KS) and Regeneron (REGN.O) for an EU-rolling review.

Rolling reviews are aimed at speeding up the approval process by allowing researchers to submit findings in real-time before final trial data is available.

Register now for FREE unlimited access to
Reporting by Pushkala Aripaka in Bengaluru, Editing by Sherry Jacob-Phillips

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters